meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab alone
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network